SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001214659-23-003941
Filing Date
2023-03-17
Accepted
2023-03-17 16:00:13
Documents
2
Group Members
CONCENTRA BIOSCIENCES, LLCKEVIN TANGTANG CAPITAL MANAGEMENT, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 o317231sc13da1.htm SC 13D/A 71872
2 GRAPHIC ktang_sig.jpg GRAPHIC 5051
  Complete submission text file 0001214659-23-003941.txt   80577
Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121 858-200-3830
TANG CAPITAL PARTNERS LP (Filed by) CIK: 0001191935 (see all company filings)

IRS No.: 680517277 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Subject) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89831 | Film No.: 23742388
SIC: 2836 Biological Products, (No Diagnostic Substances)